NCT07704424招募中不适用
Safety and Feasibility of the CorVad Percutaneous Ventricular Assist System in Refractory Right Heart Failure
Shenzhen Core Medical Technology CO.,LTD.2 个研究点 分布在 1 个国家目标入组 6 人开始时间: 2026年6月2日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 6
- 试验地点
- 2
- 主要终点
- The survival rate
研究概览
简要总结
The goal of this clinical trial is to evaluate the safety and feasibility of the CorVad Percutaneous Ventricular Assist System (Device model: CorVad RS) in patients with right heart failure who continue to experience hemodynamic instability despite best medical therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Device Feasibility
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who develop refractory right heart failure within 48 hours after left ventricular assist device (LVAD) implantation, myocardial infarction, heart transplantation, or open-heart surgery, defined as:
- •despite ongoing treatment with oral heart failure medications, including continuous infusion of high-dose inotropic agents and/or vasopressors, and/or the use of more than one inotropic agent and/or vasopressor, the cardiac index (CI) remains less than 2.2 L/min/m²;
- •and meets any one of the following criteria: 1) CVP > 15 mmHg; or, 2) CVP/pulmonary capillary wedge pressure (PCWP) or CVP/left atrial pressure (LAP) > 0.63; or, 3) echocardiographic evidence of moderate-to-severe right ventricular dysfunction meeting one of the following criteria: right ventricular basal diameter > 42 mm, right ventricular short-axis (or mid-chamber) diameter > 35 mm, tricuspid annular systolic excursion (TAPSE) score < 14 mm, right ventricular fractional area change (FAC) < 30%, tricuspid annular systolic peak velocity (TDI S') < 9 cm/s, and right ventricular free wall longitudinal strain > -20%.
- •≥ 18 years old.
- •The patient or the patient's legal representative agrees to sign the informed consent form.
排除标准
- •INTERMACS Stage 1 is defined as: despite the use of inotropic agents (positive inotropic drugs) and/or temporary mechanical support (such as IABP or ECMO), the patient remains hypotensive and shows signs of inadequate perfusion of vital organs (such as oliguria or worsening liver function), requiring immediate initiation of mechanical circulatory support to survive.
- •Severe hepatic or renal dysfunction, defined as total bilirubin ≥ 5 mg/dL or creatinine ≥ 4 mg/dL within 24 hours prior to treatment with the investigational device.
- •For patients who have undergone LVAD implantation, acute neurological injury occurring after implantation, including stroke, hypoxic encephalopathy, or acute neurological deficits (such as seizures or altered levels of consciousness).
- •Acute myocardial infarction with mechanical complications, including ventricular septal defect, cardiac rupture, or papillary muscle rupture.
- •Failed revascularization (for patients requiring right coronary revascularization), defined as a TIMI blood flow grade of 0 or 1 following percutaneous coronary intervention or coronary artery bypass grafting.
- •Active infection, meeting at least two of the following criteria: white blood cell count > 12,500/μL, positive blood culture, or fever.
- •Thrombus in the right atrium, right ventricle, and/or pulmonary artery.
- •History of mechanical valve replacement of the tricuspid or pulmonary valve.
- •Severe tricuspid stenosis or regurgitation.
- •Severe pulmonary valve stenosis or regurgitation.
- •Severe pulmonary hypertension, defined as a pulmonary artery systolic pressure > 60 mmHg.
- •Current diagnosis of pulmonary embolism.
- •History of pulmonary artery graft replacement (artificial vessel).
- •Current use of a right heart assist device or extracorporeal membrane oxygenation (ECMO) device.
- •Thrombosis of the internal jugular vein and deep veins of the lower extremities, and/or the presence of a vena cava filter.
- •Anatomical conditions that interfere with pump implantation or the safe use of the device, such as aortic dissection, Marfan syndrome, Erdheim-Chirlow disease (i.e., idiopathic medial necrosis, commonly associated with aortic dissection), etc.
- •Congenital heart disease that precludes device implantation, or an unrepairated atrial septal defect or patent foramen ovale.
- •Allergy or intolerance to contrast agents, or intolerance to anticoagulant or antiplatelet therapy.
- •History of thrombolytic therapy within the past 30 days, known coagulation disorders, or hematologic disorders causing blood cell fragility or hemolysis.
- •Female patients who are pregnant or breastfeeding.
- •Participation in any other clinical trial that may confound the study results or affect the study outcomes.
- •Other circumstances deemed by the investigator to be incompatible with inclusion in this study.
结局指标
主要结局
The survival rate
时间窗: 30 days after device explant, or hospital discharge (whichever is longer), or to the induction of anesthesia to a longer-term therapy
Feasibility endpoint at 30 days after device explant or at hospital discharge (whichever is longer) or to the induction of anesthesia to a longer-term therapy, which includes a heart transplant or an implant of a surgical right ventricular assist device (RVAD).
次要结局
- Death(30 days after device explant, 90 days after device explant)
- Major Bleeding(30 days after device explant)
- Major hemolysis(30 days after device explant)
- Pulmonary embolism(30 days after device explant)
- Tricuspid and/or pulmonary valve dysfunction(30 days after device explant)
- MACCE(30 days after device explant, 90 days after device explant)
- Changes in CVP(24 hours after CorVad support)
- Changes in CI(24 hours after CorVad support)
- Changes in LVAD flow(within 48 hours after CorVad support)
- Decreased use of inotropes/vasopressor during support(during CorVad support, after 30 days post explant and after 90 days post explant)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
不适用
Outcomes of Primary Percutaneous Coronary Intervention in Young Diabetic vs Non-Diabetic patientsCTRI/2024/07/070167VMMC and Safdarjung hospital60
招募中
3 期
Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment RegimensHIV-1-infectionNCT07683000Gilead Sciences590
尚未招募
不适用
Safety and Feasibility of Transcatheter Injectable Hydrogel in Acute STEMI Reperfusion Injury (REFINE Study)NCT07601997Myomed Technology (Shaoxing) Co., Ltd.20
尚未招募
1 期
Single-ascending Dose Study of HEC-151 InjectionNCT07376200Sunshine Lake Pharma Co., Ltd.81
招募中
2 期
Home-Based Subcutaneous Bortezomib for Patients with Multiple Myeloma and AmyloidosisCTRI/2025/01/079150TRAC50